Table 3 Association of COMMD3 expression with histopathological parameters in breast cancer
From: COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
Parameter | q Category | no. cases | % cases | p value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COMMD3 IHC score u | 0 | 1 | 2 | 3 | 4 | total | 0 | 1 | 2 | 3 | 4 | ||
Age at diagnosis |  < 50 years | 139 | 74 | 56 | 11 | 27 | 307 | 45.30% | 24.10% | 18.20% | 3.60% | 8.80% | ns |
 ≥ 50 years | 54 | 30 | 21 | 12 | 15 | 132 | 40.90% | 22.70% | 15.90% | 9.10% | 11.40% | ||
total | 193 | 104 | 77 | 23 | 42 | 439 | Â | Â | Â | Â | Â | ||
Stage | I | 11 | 8 | 6 | 1 | 2 | 28 | 39.30% | 28.60% | 21.40% | 3.60% | 7.10% | ns |
II | 56 | 22 | 17 | 2 | 7 | 104 | 53.80% | 21.20% | 16.30% | 1.90% | 6.70% | ||
III | 5 | 2 | 2 | 1 | 4 | 14 | 35.70% | 14.30% | 14.30% | 7.10% | 28.60% | ||
total | 72 | 32 | 25 | 4 | 13 | 146 | Â | Â | Â | Â | Â | ||
Grade | 1 | 21 | 15 | 8 | 5 | 12 | 61 | 34.40% | 24.60% | 13.10% | 8.20% | 19.70% | 5.80E-02 |
2 | 98 | 52 | 45 | 13 | 24 | 232 | 42.20% | 22.40% | 19.40% | 5.60% | 10.30% | ||
3 | 80 | 41 | 27 | 8 | 8 | 164 | 48.80% | 25.00% | 16.50% | 4.90% | 4.90% | ||
total | 199 | 108 | 80 | 26 | 44 | 457 | Â | Â | Â | Â | Â | ||
Mitotic score | 1 | 108 | 57 | 48 | 17 | 29 | 259 | 41.70% | 22.00% | 18.50% | 6.60% | 11.20% | 5.80E-02 |
2 | 25 | 15 | 12 | 2 | 12 | 66 | 37.90% | 22.70% | 18.20% | 3.00% | 18.20% | ||
3 | 65 | 36 | 20 | 7 | 3 | 131 | 49.60% | 27.50% | 15.30% | 5.30% | 2.30% | ||
total | 198 | 108 | 80 | 26 | 44 | 456 | Â | Â | Â | Â | Â | ||
Tubule score | T1/2 | 35 | 28 | 21 | 7 | 22 | 113 | 31.00% | 24.80% | 18.60% | 6.20% | 19.50% | 3.00E-04 |
T3 | 164 | 80 | 59 | 19 | 22 | 344 | 47.70% | 23.30% | 17.20% | 5.50% | 6.40% | ||
total | 199 | 108 | 80 | 26 | 44 | 457 | Â | Â | Â | Â | Â | ||
ER/HER2 subtype | ER-/HER2- | 47 | 18 | 10 | 2 | 0 | 77 | 61.00% | 23.40% | 13.00% | 2.60% | 0.00% | 5.40E-05 |
ER-/HER2 +  | 9 | 3 | 10 | 2 | 5 | 29 | 31.00% | 10.30% | 34.50% | 6.90% | 17.20% | ||
total | 56 | 21 | 20 | 4 | 5 | 106 | Â | Â | Â | Â | Â | ||
ER + /HER2- | 133 | 80 | 52 | 19 | 36 | 320 | 41.60% | 25.00% | 16.30% | 5.90% | 11.30% | ns | |
ER + /HER2 +  | 8 | 6 | 7 | 3 | 3 | 27 | 29.60% | 22.20% | 25.90% | 11.10% | 11.10% | ||
total | 141 | 86 | 59 | 22 | 39 | 347 | Â | Â | Â | Â | Â | ||
Histological type | IC (NST) | 112 | 59 | 62 | 16 | 24 | 273 | 41.00% | 21.60% | 22.70% | 5.90% | 8.80% | 5.50E-02 |
ILC & variants | 29 | 11 | 8 | 5 | 8 | 61 | 47.50% | 18.00% | 13.10% | 8.20% | 13.10% | ||
mixed ducto-lob | 18 | 13 | 3 | 0 | 4 | 38 | 47.40% | 34.20% | 7.90% | 0.00% | 10.50% | ||
mixed IC + special type | 20 | 9 | 3 | 1 | 2 | 35 | 57.10% | 25.70% | 8.60% | 2.90% | 5.70% | ||
metaplastic | 8 | 3 | 3 | 2 | 0 | 16 | 50.00% | 18.80% | 18.80% | 12.50% | 0.00% | ||
special types | 12 | 12 | 1 | 2 | 6 | 33 | 36.40% | 36.40% | 3.00% | 6.10% | 18.20% | ||
total | 199 | 107 | 80 | 26 | 44 | 456 | Â | Â | Â | Â | Â | ||
Prognostic subgroups | HER2 +  | 17 | 9 | 17 | 5 | 8 | 56 | 30.40% | 16.10% | 30.40% | 8.90% | 14.30% | 4.40E-02 |
ER + (Ki67-low) | 114 | 67 | 43 | 14 | 30 | 268 | 42.50% | 25.00% | 16.00% | 5.20% | 11.20% | ||
ER + (Ki67-high) | 11 | 7 | 5 | 2 | 4 | 29 | 37.90% | 24.10% | 17.20% | 6.90% | 13.80% | ||
TN (basal-like) | 35 | 15 | 7 | 2 | 0 | 59 | 59.30% | 25.40% | 11.90% | 3.40% | 0.00% | ||
TN (non-basal) | 8 | 3 | 3 | 0 | 0 | 14 | 57.10% | 21.40% | 21.40% | 0.00% | 0.00% | ||
total | 185 | 101 | 75 | 23 | 42 | 426 | Â | Â | Â | Â | Â | ||